Lb Pharmaceuticals (LBRX) Net Cash Flow (2024 - 2026)

Lb Pharmaceuticals' Net Cash Flow history runs 3 years deep, the most recent figure standing at $70.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 2339.49% year-over-year to $70.5 million; the TTM figure through Mar 2026 stood at $48.0 million (changed N/A YoY), while the FY2025 annual figure was $227.5 million, up 2577.12% from the prior year.
• Net Cash Flow for Q1 2026 stood at $70.5 million, up from -$19.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $70.5 million in Q1 2026, with the low at -$19.3 million in Q4 2025.
• The 3-year median for Net Cash Flow is $2.4 million (2024), against an average of $14.0 million.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow sank 345.27% in 2025, then soared 2339.49% in 2026.
• Lb Pharmaceuticals' Net Cash Flow stood at $7.9 million in 2024, then slumped by 345.27% to -$19.3 million in 2025, then jumped by 465.09% to $70.5 million in 2026.
• Business Quant data shows LBRX's Net Cash Flow at $70.5 million in Q1 2026, -$19.3 million in Q4 2025, and -$3.1 million in Q1 2025.